Disease landscape
Lung cancer (NSCLC)
GAP analysis for NSCLC revealed moderate restrictions in access to both diagnosis and treatment. The combined indicator varies moderately across the countries with differences of about 10 points. The gaps are driven mainly by the limited access to registered drugs, either due to lack of reimbursement or population limitations, including come restrictions in access to PD-1/PD-L inhibitor drugs, which results in a moderate proportion of patients treated with this group of drugs.
Cross-Country
General GAP for NSCLC
Compliance with guidelines
Of the 25 drugs recommended by the ESMO clinical practice guidelines, on average, about 55-60% are available in the V4 countries. There are some differences in the access to newly authorized drugs - the results varied across the countries by 16 percentage points.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
pd-1/pd-l1
Drug access
Number of patientS treated
Drug access
Population treated (%)
Main issues
- The average time to reimbursement for NSCLC drugs in the V4 countries is more than 2.6 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 2.0 years.
- The proportion of patients in the target population treated with PD-1/PD-L1 inhibitor drugs in V4 countries varied widely between the V4 states in 2021: from 4% in Slovakia, through 32-37% in Hungary and Poland up to 61% in Czechia.
- The population burden defined by DALYs (disability adjusted life-years) in lung cancer is significant in all V4 countries.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).